Immunisation policies - Success, failures and the future

Journal of Clinical Pathology

Volumn 49, Issue 8, 1996, Pages 620-622

  Miller, Elizabeth ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MEASLES VACCINE; MUMPS VACCINE; POLIOMYELITIS VACCINE; RUBELLA VACCINE; TETANUS TOXOID; VACCINE;

HISTORY; HUMAN; IMMUNIZATION; PRIORITY JOURNAL; SHORT SURVEY; ARTICLE; DRUG DELIVERY SYSTEM; METHODOLOGY; PREVENTIVE HEALTH SERVICE; WORLD HEALTH ORGANIZATION;

DRUG DELIVERY SYSTEMS; HUMANS; IMMUNIZATION PROGRAMS; VACCINES; WORLD HEALTH ORGANIZATION;

EID: 0029662355     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.49.8.620     Document Type: Short Survey

References (17)

1. Sabin AB, Oral poliovirus vaccine: History of its development and use and current challenge to eliminate poliomyelitis from the world. J Infect Dis 1985;151:420-36.
2. Agol VI, Segei GD. Russian contribution to OPV. Biolgicals 1993;21:321-5.
3. Slack MPE. Invasive Haemophilus influenzae disease: the impact of Hib immunisation. J Med Microbiol 1995;42:75-7.
4. Anonymous. Progress toward elimination of Haemophilus influenzae type b disease among infants and children - United States, 1993-1994, MMWR 1995;44:545-50.
5. Anonymous. Certification of poliomyelitis eradication - the Americas, 1994. MMWR 1994;43:720-2.
6. Anonymous, Measles elimination in the Americas. Bulletin of the Pan American Health Organisation 1992;26:271-4.
7. Gindler JS, Atkinson WL, Markowitz LE. Update - the United States measles epidemic, 1989-1990. Epidemiol Rev 1992;14:270-5.
8. Gay NJ, Hesketh LM, Morgan-Capner P, Miller E. Interpretation of serological surveillance data for measles using mathematical models: implications for vaccine strategy. Epidemiol Infect 1995;115:139-56.
9. Chief Medical Officer. Measles, rubella (MR) immunisation campaign 1994: one year on. CMO's Update 1995;(8):1.
10. Brown DWG, Ramsay MEB, Richards AF, Miller E. Salivary diagnosis of measles in the United Kingdom, 1991-3. BMJ 1994;308:1015-17.
11. Rota JS, Heath JL, Rota PA, King GE, Celma ML, Carabana J, et al. Molecular epidemiology of measles virus: identification of pathways of transmission and implications for measles elimination. J Infect Dis 1946;173:32-7.
12. World Bank. World development report 1993. Investing in health. New York: Oxford University Press, 1993.
13. Aaby P, Knudsen K, Whittle H, Lisse IM, Thaarup J, Poulsen A, et al. Long-term survival after Edmonston-Zagreb measles vaccination in Guinea-Bissau: Increased female mortality rate. J Pediatr 1993;122:904 -8.
14. Rauch LW, Schmidt R. Measles immunisation with killed measles virus. Am J Dis Child 1965:109:232-7.
15. Rabinovitch NR, McInnes P, Kelin DL, Fenton Hall B. Vaccine technologies: view to the future. Science 1994; 265:1401-4.
16. Morris W, Steinhoff MC, Russell PK. Potential of polymer microencapsulation technology for vaccine innovation. Vaccine 1994;12:5-11.
17. Rickman LS, Gordon DM, Wistar R, Krzych U, Gross M, Hollingdale MR, et al. Use of adjuvant containing mycobacterial cell-wall skeleton, monophosphoryl lipid A, and squalene in malaria circumsporozoite protein vaccine. Lancet 1991;337:998.